- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
- Ocugen Provides Business Update with First Quarter 2024 Financial Results
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
- Ocugen to Present at May 2024 Investor Conferences
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
More ▼
Key statistics
On Thursday, Ocugen Inc (OCGN:NAQ) closed at 1.78, -15.44% below its 52-week high of 2.11, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.75 |
---|---|
High | 1.82 |
Low | 1.68 |
Bid | 1.76 |
Offer | 1.79 |
Previous close | 1.72 |
Average volume | 7.69m |
---|---|
Shares outstanding | 257.33m |
Free float | 253.26m |
P/E (TTM) | -- |
Market cap | 458.04m USD |
EPS (TTM) | -0.2348 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼